Urology Times
The ModernMedicine Network is a comprehensive platform that unites news, resources, tools, and educational programs from reliable and respected sources. It is curated by a team of experts, including advisors, consultants, influential voices, and content partners. ModernMedicine serves as a central news source for professionals in the healthcare industry.
Outlet metrics
Global
#351494
United States
#124390
Health/Medicine
#1040
Articles
-
2 days ago |
urologytimes.com | Mark Tyson |Bogdana Schmidt |Sam S. Chang |Aaron Berger
Author(s):,Panelists discuss how recent trials, including KEYNOTE-057, QUILT-3.032, and CORE-001, highlight the promising efficacy, durability, and manageable safety profiles of novel treatments like pembrolizumab, nogapendekin alfa inbakicept, and nadofaragene firadenovec, while also exploring the potential of combination therapies and novel intravesical options like TAR-200 and UGN-102 for improving outcomes in non–muscle-invasive bladder cancer (NMIBC).
-
2 days ago |
urologytimes.com | Mark Tyson |Bogdana Schmidt |Sam S. Chang |Aaron Berger
Author(s):,Panelists discuss how the ongoing ABLE-32 and ABLE-41 trials are exploring the efficacy and safety of nadofaragene firadenovec in different NMIBC patient populations, with ABLE-32 focusing on intermediate-risk patients and ABLE-41 examining real-world effectiveness and safety. The ongoing clinical trials investigating nadofaragene firadenovec include the ABLE-32 and ABLE-41 trials, each focusing on different aspects of its use in treating non-muscle invasive bladder cancer (NMIBC).
-
6 days ago |
urologytimes.com | Benjamin P. Saylor
Findings of an exploratory analysis of the phase 3 NIAGARA trial (NCT03732677) evaluating perioperative durvalumab (Imfinzi) plus neoadjuvant chemotherapy (NAC) with radical cystectomy vs NAC with radical cystectomy alone appear to support the utility of circulating tumor DNA (ctDNA) as a biomarker in the neoadjuvant setting.1 The findings also lend further credence to this muscle-invasive bladder cancer treatment regimen, investigators reported at the 2025 American Society of Clinical...
-
6 days ago |
urologytimes.com | Benjamin P. Saylor
For patients with untreated unresectable or metastatic urothelial carcinoma who are not eligible for cisplatin, combination nivolumab (Opdivo) plus ipilimumab (Yervoy) did not achieve statistical significance for the end point of overall survival (OS), according to data from the phase 3 CheckMate 901 trial (NCT03036098).1 However, the treatment combination did show a notable duration of response and “favorable landmark OS after 12 months,” according to Michiel Van der Heijden, MD, PhD,...
-
6 days ago |
urologytimes.com | Silas Inman
Adjuvant treatment with pembrolizumab (Keytruda) continued to show consistent overall survival (OS) and disease-free survival (DFS) benefits compared with placebo for patients with clear cell renal cell carcinoma (ccRCC), according to a landmark 5-year analysis of the phase 3 KEYNOTE-564 study (NCT03142334) presented at the 2025 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois.
Urology Times journalists
Contact details
Address
123 Example Street
City, Country 12345
Phone
+1 (555) 123-4567
Email Patterns
Website
http://urologytimes.comTry JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →